Latest Novartis News & Updates

See the latest news and media coverage for Novartis. We track all announcements, press releases, and industry mentions in real time, all in one place.

Novartis

Innovative medicines company

novartis.com

Headquarters: Basel, Switzerland
Company type: Public company
Number of employees: 85,000+
Industry: Pharmaceuticals

Last updated Today

Latest news about Novartis

In short: Novartis experienced significant stock declines following major late-stage trial failures, even as it secured several key drug approvals.

Company announcements

September 8 Novartis

Novartis reports del-desiran Phase III trial misses primary endpoint

The therapy shows activity in secondary analyses. Novartis will analyze full data and consult regulators while advancing other neuromuscular programs.

September 4 Novartis

Novartis announces pelacarsen cardiovascular trial fails primary endpoint

The study achieved lower lipoprotein(a) levels but did not reduce cardiovascular events compared to placebo in over 8,000 patients with established disease.

August 6 Novartis

Novartis terminates its Zolgensma global managed access program

The five-year initiative treated nearly three hundred children across forty nations before transitioning to commercial approvals in more than fifty countries.

July 31 Novartis

Novartis announces FDA approval of Pluvicto for mHSPC

The approval expands Pluvicto's use to PSMA-positive metastatic hormone-sensitive prostate cancer, nearly doubling eligible patients. Phase III PSMAddition showed 33% risk reduction in progression or death.

Media coverage

Today cash

Missed endpoint in Phase II study: Novartis ends research program with ALS candidate

The pharmaceutical company Novartis has halted the development of the drug candidate VHB937 for the treatment of amyotrophic lateral sclerosis (ALS).

Yesterday Yahoo Finance

FDA clears first generic radioligand drug; Sionna turns to layoffs

A Lutathera copycat has become the first “radioligand equivalent” cleared by regulators. Elsewhere, ...

September 11 Barron's

Novartis: More Pain on the Way?

The bad diagnoses just keep on coming for the Swiss drugmaker.

September 11 Devdiscourse

Novartis' M&A Strategy Under Investor Scrutiny After Drug Setbacks

Novartis faces increased investor scrutiny over its mergers and acquisitions strategy following setbacks with acquired drugs.

Never miss news about Novartis

Track Novartis and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Novartis competitors & trending companies

Browse news for competitors to Novartis and other trending companies.